US 11,986,453 B2
Stable pharmaceutical composition containing non-steroidal anti-inflammatory drug derivative
Jing Zhang, Shanghai (CN)
Assigned to ZHEJIANG YUEJIA PHARMACEUTICALS CO., LTD, Deqing County (CN)
Filed by ZHEJIANG YUEJIA PHARMACEUTICALS CO., LTD, Deqing County (CN)
Filed on May 4, 2023, as Appl. No. 18/312,466.
Application 18/312,466 is a continuation of application No. 16/758,880, abandoned, previously published as PCT/CN2018/108622, filed on Sep. 29, 2018.
Claims priority of application No. 201711014218.2 (CN), filed on Oct. 26, 2017.
Prior Publication US 2023/0270710 A1, Aug. 31, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/245 (2006.01); A61K 9/08 (2006.01); A61K 31/216 (2006.01)
CPC A61K 31/245 (2013.01) [A61K 9/08 (2013.01); A61K 31/216 (2013.01)] 19 Claims
 
1. A transdermal pharmaceutical composition containing a solid portion and a liquid portion,
wherein the solid portion comprises a non-steroidal anti-inflammatory drug derivative salt thereof selected from the group consisting of 2-(diethylamino)-ethyl-2-acetoxybenzoate hydrochloride, salicylic acid-(2-diethylaminoethyl ester) hydrochloride, and 2-(diethylamino)-ethyl-2-(4-isobutylphenyl) propionate hydrochloride and a pharmaceutically acceptable binder
selected from the group consisting of hypromellose, carbomer, ethyl cellulose, hydroxypropyl cellulose, vinyl cellulose, starch, pregelatinized starch, and polyvinylpyrrolidone, the mass ratio of said salt to the binder being from 100:0.05 to 100:10;
wherein the solid portion is stable after storing at 25° C.±2° C. for 12 months;
the solid dosage form is selected from the group consisting of powders, tablets, and granules;
the liquid portion comprises a pharmaceutically acceptable solvent
the solid portion and the liquid portion are separated prior to use and the solid portion and the liquid portion are configured to be mixed when the pharmaceutical composition is used to form a solution dosage form for external administration.